J. Houston

发表

High-throughput RT-PCR analysis of multiple transcripts using a microplate RNA isolation procedure.

M. Kendrick, F. Craig, M. Dickson, 1997, BioTechniques.

Isolation and study of an acquired inhibitor of human coagulation factor V.

T. L. Cole, K. Mann, J. Houston, 1986, The Journal of clinical investigation.

Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.

J. Macor, R. Schartman, G. Tong, 2012, Journal of medicinal chemistry.

A 384-HTS for Human Factor VIIa: Comparison With 96- and 864-Well Formats

John G. Houston, J. Comley, Alastair Binnie, 1997 .

Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays

N. Bowery, J. Phillipson, J. Lewis, 2000, Phytotherapy research : PTR.

γ-Secretase Inhibitors for Alzheimer’s Disease

C. Albright, D. Barten, J. Meredith, 2006 .

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

C. Albright, D. Barten, J. Meredith, 2006, Drugs in R&D.

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

H. Feldman, J. Macor, R. Berman, 2013, The Journal of Pharmacology and Experimental Therapeutics.

High‐Throughput Screening: Evolution of Technology and Methods

Angela Cacace, Martyn Banks, John G. Houston, 2010 .

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.

J. Macor, C. Albright, R. Olson, 2010, ACS medicinal chemistry letters.

Searching for Chemokine Receptor Binding Antagonists by High Throughput Screening

M. Congreve, M. Banks, G. Mellor, 1997 .

JPET # 199356 3 Recommended section assignment to guide listing in table of contents : Neuropharmacology

H. Feldman, J. Macor, R. Berman, 2012 .

The squalestatins: inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues.

B. Dymock, P. Procopiou, A. Craven, 1994, Journal of medicinal chemistry.

Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.

Alastair Binnie, John G Houston, Martyn N Banks, 2008, Drug discovery today.

The chemical-biological interface: developments in automated and miniaturised screening technology.

J G Houston, M Banks, M. Banks, 1997, Current opinion in biotechnology.

Application of lean manufacturing concepts to drug discovery: rapid analogue library synthesis.

Harold N Weller, John G Houston, David S. Nirschl, 2006, Journal of combinatorial chemistry.

High‐Throughput Screening for Lead Discovery

Martyn Banks, John G. Houston, M. Banks, 2003 .